Skip Navigation LinksHome > Collections > Belatacept Mediated Costimulation Blockade

Belatacept Mediated Costimulation Blockade

Creator:   K J Wood
Created:   2/16/2011
Contains:  18 items

Actions
View

An Integrated Safety Profile Analysis of Belatacept in Kidney Transplant Recipients

Purchase Access
Abstract
PDF
+ Favorites
Request Permissions

Belatacept-Based Regimens Versus a Cyclosporine A-Based Regimen in Kidney Transplant Recipients: 2-Year Results From the BENEFIT and BENEFIT-EXT Studies

Purchase Access
Abstract
PDF
+ Favorites
Request Permissions

Islet Transplantation in Type 1 Diabetic Patients Using Calcineurin Inhibitor-Free Immunosuppressive Protocols Based on T-Cell Adhesion or Costimulation Blockade

Purchase Access
Abstract
PDF
+ Favorites
Request Permissions

Low Serum Mannose-Binding Lectin as a Risk Factor for New Onset Diabetes Mellitus After Renal Transplantation

Purchase Access
Abstract
PDF
+ Favorites
Request Permissions

Belatacept as Immunosuppression in Patient With Recurrence of Hemolytic Uremic Syndrome After Renal Transplantation

Purchase Access
PDF
+ Favorites
Request Permissions

Assessment of Belatacept-Mediated Costimulation Blockade Through Evaluation of CD80/86-Receptor Saturation

Purchase Access
Abstract
PDF
+ Favorites
Request Permissions

Fibrogenesis in Kidney Transplantation: Potential Targets for Prevention and Therapy

Purchase Access
Abstract
PDF
+ Favorites
Request Permissions

A MIXED TREATMENT COMPARISON OF EFFICACY AND CARDIOMETABOLIC SAFETY OF BELATACEPT, CYCLOSPORINE AND TACROLIMUS FOR IMMUNOSUPPRESSION THERAPY IN ADULT RENAL TRANSPLANT RECIPIENTS:...

Free Access
PDF
+ Favorites
Request Permissions

OUTCOMES AS A FUNCTION OF DONOR:RECIPIENT CHARACTERISTICS FROM A PHASE III STUDY OF BELATACEPT VS CYCLOSPORINE IN KIDNEY TRANSPLANTATION (BENEFIT): 2857.

Free Access
PDF
+ Favorites
Request Permissions

SAFETY PROFILE OF BELATACEPT IN KIDNEY TRANSPLANT RECIPIENTS FROM A POOLED ANALYSIS OF PHASE II AND PHASE III STUDIES: 1417.

Free Access
PDF
+ Favorites
Request Permissions

IMMUNOSUPPRESSION WITH BELATACEPT-BASED, CNI-AVOIDING AND STEROID-AVOIDING REGIMENS VS A TACROLIMUS-BASED, STEROID-AVOIDING REGIMEN IN KIDNEY TRANSPLANT PATIENTS: RESULTS OF A...

Free Access
PDF
+ Favorites
Request Permissions

SWITCH FROM A CNI- TO A BELATACEPT-BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRANSPLANT RECIPIENTS IS SAFE AND RESULTS IN BETTER RENAL FUNCTION: 12 MONTH RESULTS FROM A PHASE II...

Free Access
PDF
+ Favorites
Request Permissions

BELATACEPT VS CYCLOSPORINE IN KIDNEY TRANSPLANT RECIPIENTS: TWO-YEAR OUTCOMES FROM THE BENEFIT STUDY: 1374.

Free Access
PDF
+ Favorites
Request Permissions

PHARMACOKINETICS, PHARMACODYNAMICS, AND IMMUNOGENICITY OF BELATACEPT IN RENAL TRANSPLANT PATIENTS: 1870.

Free Access
PDF
+ Favorites
Request Permissions

APPLICATION OF A VALIDATED LONG-TERM RENAL TRANSPLANT GRAFT SURVIVAL PREDICTION MODEL TO EXPECTED BELATACEPT PHASE III TRIAL OUTCOMES: 679.

Free Access
PDF
+ Favorites
Request Permissions

RELATIONSHIP BETWEEN BELATACEPT EXPOSURE AND CLINICAL ENDPOINTS IN RENAL TRANSPLANT PATIENTS: 1892.

Free Access
PDF
+ Favorites
Request Permissions

OUTCOMES AS A FUNCTION OF DONOR CRITERIA FROM A PHASE III STUDY OF BELATACEPT VS CYCLOSPORINE IN KIDNEY TRANSPLANTATION (BENEFIT-EXT): 1773.

Free Access
PDF
+ Favorites
Request Permissions

BENEFIT-RISK PROFILE OF THE BELATACEPT LI REGIMEN AT 2 YEARS IN EBV(+) KIDNEY TRANSPLANT RECIPIENTS: 3370.

Free Access
PDF
+ Favorites
Request Permissions
Actions
View
Collection Alerts

Stay up-to-date! Be notified every time a new item is added. Receive an Email or subscribe to an RSS feed.